Back

Association of VA Hematology/Oncology (AVAHO), France Foundation, The

  • Histocompatibility Testing
  • Uveal Melanoma

Addressing Unmet Needs in Metastatic Uveal Melanoma

TARGET AUDIENCE This educational activity is intended for ophthalmology, ocular oncology, and medical oncology physicians, APPs, and nurses and other members of the health care team who care for patients with metastatic uveal melanoma PROGRAM OVERVIEW Join leading oncologists for an expert roundtable that goes beyond the basics. In this dynamic, case-focused discussion, clinicians will sharpen their ability to distinguish uveal vs. cutaneous melanoma, confidently apply guideline-driven treatments for metastatic uveal melanoma, and understand why HLA A*02:01 testing is shaping therapeutic decisions. Discover the science behind bispecific TCR therapy, unpack real-world clinical trial data, and learn how these advances translate into better outcomes especially in the VA care setting. LEARNING OBJECTIVES Upon completion of this course, the learners should be able to: Differentiate uveal from cutaneous melanoma Explain the importance of HLA typing in patients with uveal melanoma Explain the mechanism of action of novel bispecific TCR therapy Interpret efficacy and safety clinical trial data on the use of bispecific TCR therapy in patients with mUM

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AMA PRA Category 1 Credit™Up to 1 credit

MOC types

No MOC

FDA REMS

No

Qualifies for MIPS

No

Pricing

Free

Reported to ACCME by the provider

  • Case-based learning
  • Credit · Up to 1 credit
  • Commercial Support
  • Released
    Dec 19, 2025
  • Last day to claim credit
    Dec 19, 2026 2 months left